Novavax, Inc. (NASDAQ:NVAX) is set to announce third quarter earning results on Monday 9th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, NVAX to report 3Q20 income of $ 1.73 per share from revenue of $ 230.56 million.
For the full year, analysts anticipate top line of $ 971.44 million, while looking forward to income of $ 6.97 per share bottom line.
Previous Quarter Performance
Novavax, Inc. came out with loss for the second quarter of $ 0.30 per share, from the revenue of $ 35.54 million. The quarterly revenues gained 1,061.44 percent compared with the same quarter last year. Wall street analysts are predicting, NVAX to report 2Q20 loss of $ 0.42 per share from revenue of $ 39.58 million. The bottom line results beat street analysts by $ 0.12 or 28.57 percent, at the same time, top line results fell short of analysts by $ 4.04 million or 10.21 percent.
Stock Performance
On Friday, shares of Novavax, Inc. has traded high as $ 92.86 and has cracked $ 88.25 on the downward trend, reaching $ 89.86 with volume of 1.89 million shares.
According to the previous trading day, closing price of $ 89.86, representing a 2,530.23 % increase from the 52 week low of $ 3.54 and a 50.84 % decrease over the 52 week high of $ 189.40.
The company has a market capital of $ 5.51 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Novavax, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.novavax.com
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The companys lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen.
